<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618056</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 121</org_study_id>
    <secondary_id>38162</secondary_id>
    <nct_id>NCT03618056</nct_id>
  </id_info>
  <brief_title>Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the breadth and potency of HIV-1 neutralizing&#xD;
      antibody (nAb) responses and examine the safety and tolerability of an HIV gp120 protein&#xD;
      vaccine (AIDSVAX® B/E) in HIV-uninfected adults diagnosed with Systemic Lupus Erythematosus&#xD;
      (SLE) who have stable disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the breadth and potency of HIV-1 neutralizing antibody (nAb)&#xD;
      responses and examine the safety and tolerability of an HIV gp120 protein vaccine (AIDSVAX®&#xD;
      B/E) in HIV-uninfected adults diagnosed with Systemic Lupus Erythematosus (SLE) who have&#xD;
      stable disease.&#xD;
&#xD;
      All participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.&#xD;
&#xD;
      Study visits will occur at Months 0, 0.25, 0.5, 1, 1.25, 1.5, 3, 6, 6.25, 6.5, 7.5, 8.5, and&#xD;
      12. Visits may include physical examinations, blood and urine collection, pregnancy testing,&#xD;
      HIV testing, risk reduction counseling, assessments, and questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">September 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in response rates of nAb responses to the vaccine strains and a global panel of heterologous env-pseudotyped viruses</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by TZM-bl assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in magnitude of nAb responses to the vaccine strains and a global panel of heterologous env-pseudotyped viruses</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by TZM-bl assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breadth of nAb responses to the vaccine strains and a global panel of heterologous env-pseudotyped viruses</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by TZM-bl assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of local and systemic reactogenicity signs and symptoms</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July, 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of local and systemic reactogenicity signs and symptoms</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July, 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>AEs categorized by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class, and MedDRA Preferred Term</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of SLE disease activity and functional status</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>As assessed by Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) and Routine Assessment of Patient Index Data (RAPID3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in somatic hypermutation in participants with SLE compared with historical controls</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in length of antibody binding loops and germline gene usage in participants with SLE compared with historical controls</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NAb responses to viruses with altered glycosylation, indicative of bnAb precursors</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by TZM-bl assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vaccine-induced immune activation</measure>
    <time_frame>Measured through Month 6.25</time_frame>
    <description>Assessed by serum cytokine analysis and B and T cell phenotyping, as well as expression of Treg and Tfh markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in response rate of HIV-1-specific IgG binding antibodies</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by Binding Antibody Multiplex Assay (BAMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in magnitude of HIV-1-specific IgG binding antibodies</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by BAMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in specificity of antibody responses</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Assessed by epitope mapping of functional and binding antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in response rate of Env-specific CD4+ T cells</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Measured by intracellular cytokine staining (ICS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in magnitude of Env-specific CD4+ T cells</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Measured by ICS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in polyfunctionality of Env-specific CD4+ T cells</measure>
    <time_frame>Measured through Month 6.5</time_frame>
    <description>Measured by ICS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>HIV Infections</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>AIDSVAX® B/E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 600 mcg/mL of AIDSVAX® B/E at Months 0, 1, and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIDSVAX® B/E</intervention_name>
    <description>Administered by intramuscular injection</description>
    <arm_group_label>AIDSVAX® B/E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General and Demographic Criteria&#xD;
&#xD;
          -  Age of 18 to 50 years&#xD;
&#xD;
          -  Weight greater than 110 pounds&#xD;
&#xD;
          -  Meets American College of Rheumatology (ACR) criteria for the classification of SLE&#xD;
             with serologic evidence of disease including a positive test for antinuclear&#xD;
             antibodies at a titer of 1:640 or greater, or the presence of a positive test for&#xD;
             antibodies to double-strand DNA (dsDNA), or the presence of anti-Sm, anti-RNP, or&#xD;
             anti-Ro antibodies, as documented by medical records and as assessed by a&#xD;
             rheumatologist or designee.&#xD;
&#xD;
          -  Currently taking hydroxychloroquine for SLE and for at least 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site&#xD;
             (CRS) and willingness to be followed for the planned duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
          -  Allows ongoing access to medical records pertaining to their rheumatologic disease&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study;&#xD;
             completes a questionnaire prior to first vaccination with verbal demonstration of&#xD;
             understanding of all questionnaire items answered incorrectly&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent before the&#xD;
             last required protocol clinic visit&#xD;
&#xD;
        HIV-Related Criteria:&#xD;
&#xD;
          -  Willingness to receive HIV test results&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and amenable to HIV risk reduction&#xD;
             counseling.&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection and committed to&#xD;
             maintaining behavior consistent with low risk of HIV exposure through the last&#xD;
             required protocol clinic visit (see protocol for more information)&#xD;
&#xD;
        Laboratory Inclusion Values&#xD;
&#xD;
        Hemogram/Complete blood count (CBC)&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were assigned female&#xD;
             sex at birth, greater than or equal to 12.0 g/dL for volunteers who were assigned male&#xD;
             sex at birth.&#xD;
&#xD;
          -  White blood cell count equal to 2,500 to 12,000 cells/mm^3&#xD;
&#xD;
          -  Total lymphocyte count greater than or equal to 800 cells/mm^3&#xD;
&#xD;
          -  Remaining differential either within institutional normal range or with site physician&#xD;
             approval&#xD;
&#xD;
          -  Platelets equal to 100,000 to 550,000/mm^3&#xD;
&#xD;
        Chemistry&#xD;
&#xD;
          -  Chemistry panel: alanine amino transferase (ALT) and aspartate aminotransferase (AST)&#xD;
             less than 1.25 times the institutional upper limit of normal; creatinine less than or&#xD;
             equal to institutional upper limit of normal.&#xD;
&#xD;
        Virology&#xD;
&#xD;
          -  Negative HIV-1 and -2 blood test: volunteers must have a negative US Food and Drug&#xD;
             Administration (FDA)-approved enzyme immunoassay (EIA) within 56 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Negative Hepatitis B surface antigen (HBsAg) within 56 days prior to enrollment&#xD;
&#xD;
          -  Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase&#xD;
             chain reaction (PCR) if the anti-HCV is positive within 56 days prior to enrollment&#xD;
&#xD;
        Urine&#xD;
&#xD;
          -  Normal urine by urinalysis:&#xD;
&#xD;
               -  Negative urine glucose, and&#xD;
&#xD;
               -  Negative or trace urine protein, and&#xD;
&#xD;
               -  Red blood cell (RBC) levels within institutional normal range, and&#xD;
&#xD;
               -  No RBC casts&#xD;
&#xD;
        Reproductive Status&#xD;
&#xD;
          -  Volunteers who were assigned female sex at birth: negative serum or urine beta human&#xD;
             chorionic gonadotropin (β-HCG) pregnancy test in accordance with local regulatory&#xD;
             requirements, performed prior to vaccination on the day of initial vaccination.&#xD;
             Persons who are NOT of reproductive potential due to having undergone total&#xD;
             hysterectomy or bilateral oophorectomy (verified by medical records), are not required&#xD;
             to undergo pregnancy testing.&#xD;
&#xD;
          -  Reproductive status: A volunteer who was assigned female sex at birth must:&#xD;
&#xD;
               -  Agree to use effective contraception for sexual activity that could lead to&#xD;
                  pregnancy from at least 21 days prior to enrollment through the last required&#xD;
                  protocol clinic visit. Effective contraception is defined as using the following&#xD;
                  methods:&#xD;
&#xD;
                    -  Condoms (male or female) with or without a spermicide,&#xD;
&#xD;
                    -  Diaphragm or cervical cap with spermicide,&#xD;
&#xD;
                    -  Intrauterine device (IUD),&#xD;
&#xD;
                    -  Hormonal contraception, or&#xD;
&#xD;
                    -  Any other contraceptive method approved by the HVTN 121 Protocol Safety&#xD;
                       Review Team (PSRT)&#xD;
&#xD;
                    -  Successful vasectomy in any partner assigned male sex at birth (considered&#xD;
                       successful if a volunteer reports that a male partner has [1] documentation&#xD;
                       of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with&#xD;
                       no resultant pregnancy despite sexual activity postvasectomy);&#xD;
&#xD;
               -  Or not be of reproductive potential, such as having reached menopause (no menses&#xD;
                  for 1 year) or having undergone hysterectomy, bilateral oophorectomy, or tubal&#xD;
                  ligation;&#xD;
&#xD;
               -  Or be sexually abstinent.&#xD;
&#xD;
          -  Volunteers who were assigned female sex at birth must also agree not to seek pregnancy&#xD;
             through alternative methods, such as artificial insemination or in vitro fertilization&#xD;
             until after the last required protocol clinic visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Blood products received within 120 days before first vaccination&#xD;
&#xD;
          -  Investigational research agents not used to treat SLE received within 30 days before&#xD;
             first vaccination (additional exclusions may apply, see criteria below)&#xD;
&#xD;
          -  Intent to participate in another study of an investigational research agent or any&#xD;
             other study that requires non-HVTN HIV antibody testing during the planned duration of&#xD;
             the HVTN 121 study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active duty and reserve US military personnel&#xD;
&#xD;
        SLE status. The following criteria must be verified by a rheumatologist or designee&#xD;
&#xD;
          -  Currently with active lupus as defined by a Systemic Lupus Erythematosus Disease&#xD;
             Activity Index (SELENA-SLEDAI) greater than 4 (see protocol for more information).&#xD;
&#xD;
          -  Documented SLEDAI score of greater than 20 in medical record at any time indicating&#xD;
             severe activity, or evidence of moderate disease activity (SELENA-SLEDAI greater than&#xD;
             6) within the last six months, (see protocol for more information).&#xD;
&#xD;
          -  Has had a condition listed on the Systemic Lupus International Collaborating&#xD;
             Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) or has had an&#xD;
             increase in the SLICC/ACR D1 score within the last 12 months other than cataracts,&#xD;
             premature ovarian failure or diabetes mellitus with approval of the PSRT&#xD;
             http://www.clinexprheumatol.org/article.asp?a=2697&#xD;
&#xD;
          -  A history of central nervous system (CNS) disease&#xD;
&#xD;
          -  Thrombotic event within the past 12 months in association with confirmed&#xD;
             antiphospholipid antibody&#xD;
&#xD;
          -  A history of renal disease (SLE-related renal injury) confirmed by prior biopsy,&#xD;
             active urine sediment, or proteinuria&#xD;
&#xD;
          -  Prednisone dose greater than 10 mg/day for more than 6 months within the past year&#xD;
&#xD;
          -  Administration of anti-B-cell therapy (rituximab or belimumab) or any investigational&#xD;
             research agents used to treat SLE within the preceding 2 years&#xD;
&#xD;
          -  Administration of cyclophosphamide within the preceding year; or administration of&#xD;
             mycophenolate mofetil within the last 6 months; or administration of methotrexate,&#xD;
             leflunomide, or azathioprine within the last 3 months&#xD;
&#xD;
          -  Administration of any investigational immunosuppressant medication within the last&#xD;
             year&#xD;
&#xD;
          -  Administration of other immunosuppressive medications not listed above, with the&#xD;
             exception of topical steroids, topical immunosuppressives (eg, cyclosporine, FK506),&#xD;
             or ophthalmic immunosuppressives (eg, steroids, cyclosporine), within 6 months before&#xD;
             first vaccination, unless approved by the HVTN 121 PSRT&#xD;
&#xD;
        Vaccines and other Injections&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received&#xD;
             control/placebo in an HIV vaccine trial, the HVTN 121 PSRT will determine eligibility&#xD;
             on a case-by-case basis.&#xD;
&#xD;
          -  Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine&#xD;
             trial. Exceptions may be made by the HVTN 121 PSRT for vaccines that have subsequently&#xD;
             undergone licensure by the FDA. For volunteers who have received control/placebo in an&#xD;
             experimental vaccine trial, the HVTN 121 PSRT will determine eligibility on a&#xD;
             case-by-case basis. For volunteers who have received an experimental vaccine(s)&#xD;
             greater than 5 years ago, eligibility for enrollment will be determined by the HVTN&#xD;
             121 PSRT on a case-by-case basis.&#xD;
&#xD;
          -  Vaccines received within 30 days before first study vaccination or scheduled within 30&#xD;
             days after injection (eg, influenza, tetanus, pneumococcal, Hepatitis A or B, measles,&#xD;
             mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)&#xD;
&#xD;
          -  Allergy treatment with antigen injections within 30 days before first vaccination or&#xD;
             that are scheduled within 14 days after first vaccination&#xD;
&#xD;
        Immune System&#xD;
&#xD;
          -  Serious adverse reactions to vaccines or to vaccine components (such as yeast protein,&#xD;
             amorphous aluminum hydroxyphosphate sulfate, L-histidine, polysorbate 80, sodium&#xD;
             borate), including history of anaphylaxis and related symptoms such as hives,&#xD;
             respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from&#xD;
             participation: a volunteer who had a nonanaphylactic adverse reaction to pertussis&#xD;
             vaccine as a child.)&#xD;
&#xD;
          -  Immunoglobulin received within 60 days before first vaccination&#xD;
&#xD;
          -  Immunodeficiency, such as common variable immunodeficiency&#xD;
&#xD;
        Clinically significant medical conditions&#xD;
&#xD;
          -  Ongoing bleeding or hemorrhage (excluding menstruation), or any subject on&#xD;
             anticoagulant therapy&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, clinically&#xD;
             significant abnormal laboratory results, or past medical history with clinically&#xD;
             significant implications for current health, other than SLE and its manifestations. A&#xD;
             clinically significant condition or process includes but is not limited to:&#xD;
&#xD;
               -  A process that would affect the immune response,&#xD;
&#xD;
               -  A process that would require medication that affects the immune response,&#xD;
&#xD;
               -  Any contraindication to repeated injections or blood draws,&#xD;
&#xD;
               -  A condition that requires active medical intervention or monitoring to avert&#xD;
                  grave danger to the volunteer's health or well-being during the study period,&#xD;
&#xD;
               -  A condition or process for which signs or symptoms could be confused with&#xD;
                  reactions to vaccine, or&#xD;
&#xD;
               -  Any condition specifically listed among the exclusion criteria below.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, assessment of safety or reactogenicity, or a volunteer's ability to give&#xD;
             informed consent&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) prophylaxis or therapy&#xD;
&#xD;
          -  Asthma exclusion criteria: Asthma other than mild, well-controlled asthma. (Symptoms&#xD;
             of asthma severity as defined in the most recent National Asthma Education and&#xD;
             Prevention Program (NAEPP) Expert Panel report). Exclude a volunteer who:&#xD;
&#xD;
               -  Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or&#xD;
&#xD;
               -  Uses moderate/high dose inhaled corticosteroids, or&#xD;
&#xD;
               -  In the past year has either of the following:&#xD;
&#xD;
                    -  Greater than 1 exacerbation of symptoms treated with oral/parenteral&#xD;
                       corticosteroids;&#xD;
&#xD;
                    -  Needed emergency care, urgent care, hospitalization, or intubation for&#xD;
                       asthma.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, Hb A1C greater than 7.0. (not excluded: history of&#xD;
             isolated gestational diabetes.)&#xD;
&#xD;
          -  Uncontrolled hypertension:&#xD;
&#xD;
               -  If a person has a history of hypertension, or is found to have elevated blood&#xD;
                  pressure or hypertension during screening, exclude for blood pressure that is not&#xD;
                  well controlled. Well-controlled blood pressure is defined as consistently less&#xD;
                  than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic,&#xD;
                  with only isolated, brief instances of higher readings, which must be less than&#xD;
                  or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg diastolic. For&#xD;
                  these volunteers, blood pressure must be less than or equal to 140 mm Hg systolic&#xD;
                  and less than or equal to 90 mm Hg diastolic at enrollment.&#xD;
&#xD;
               -  If a person has NOT been found to have elevated blood pressure or hypertension&#xD;
                  during screening or previously, exclude for systolic blood pressure greater than&#xD;
                  or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or&#xD;
                  equal to 100 mm Hg at enrollment.&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
          -  Malignancy (not excluded from participation: Volunteer who has had malignancy excised&#xD;
             surgically and who, in the investigator's estimation, has a reasonable assurance of&#xD;
             sustained cure, or who is unlikely to experience recurrence of malignancy during the&#xD;
             period of the study)&#xD;
&#xD;
          -  Seizure disorder: History of seizure(s) within past three years. Also exclude if&#xD;
             volunteer has used medications in order to prevent or treat seizure(s) at any time&#xD;
             within the past 3 years.&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen (not excluded:&#xD;
             splenectomy for splenic trauma)&#xD;
&#xD;
          -  History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Anthony Moody</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Goepfert</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Human Vaccine Institute CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT03618056/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>October 13, 2021</submitted>
    <returned>November 10, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

